Clinical trials: Advanced Non-Small Cell Lung Cancer (NSCLC)
- Condition Advanced Non-Small Cell Lung Cancer (NSCLC)
- Funder type Industry (pharma, biotech, devices)
Advanced Non-small Cell Lung Cancer
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy.
- Trial name
- NCT05001724
- Testing
- KN046, Lenvatinib, Docetaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Non-Squamous Non-Small Cell Lung Cancer
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line…
- Trial name
- NCT01659970
- Where
- 110 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Treatment, Treatment Side Effects
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small…
- Trial name
- NCT05767866
- Testing
- YK-029A
- Where
- 35 sites in China
- Volunteers
- 160 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
Non-Small-Cell Lung Carcinoma
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
- Trial name
- NCT00112346
- Testing
- Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
- Where
- 38 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic NSCLC
PBF-1129 in Patients With NSCLC
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist.
- Trial name
- NCT03274479
- Testing
- PBF-1129
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Palobiofarma SL
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Advanced Non-small Cell Lung Cancer
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II…
- Trial name
- NCT06585059
- Testing
- TQB2928 injection + Almonertinib Mesilate Tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in…
- Trial name
- NCT02109653
- Testing
- LGX818
- Where
- United States
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer.
- Trial name
- NCT04974957
- Testing
- SHR-1701；BP102
- Volunteers
- 71 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of…
- Trial name
- NCT07538804
- Testing
- ANS02
- Where
- 5 sites in United States, China
- Volunteers
- 294 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Non-Small Cell Lung Cancer
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT04239833
- Testing
- SH-1028 tablets, Gefitinib
- Volunteers
- 240 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Non-small-cell Lung Cancer (NSCLC) Stage IV
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer
- Trial name
- NCT03083743
- Testing
- Recombinant human Apo-2 ligand for Injection
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Shanghai Gebaide Biotechnology Co., Ltd.
Non-Small Cell Lung Cancer
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or…
- Trial name
- NCT07362940
- Testing
- GEN-725 tablets + Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 110 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care…
- Trial name
- COCOON (NCT06120140)
- Testing
- Amivantamab IV, Amivantamab SC, Lazertinib
- Where
- 93 sites in United States, Argentina and 9 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Advanced or Metastatic NSCLC
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
- Trial name
- NCT05435248
- Testing
- HS-10375
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria in patients with EGFR FISH positive…
- Trial name
- NCT00796549
- Testing
- BiBW 2992
- Where
- 13 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L)…
- Trial name
- NCT05469178
- Testing
- Bemcentinib, Pembrolizumab, Pemetrexed
- Where
- 34 sites in United States, France and 5 more
- Volunteers
- 26 people
- Sponsor
- BerGenBio ASA
Advanced Oligometastatic Non-small Cell Lung Cancer
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04306926
- Testing
- TQB2450, SBRT
- Where
- 4 sites in China
- Volunteers
- 59 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor, Glioblastoma
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid…
- Conditions
- Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04982926
- Testing
- TAS2940
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Taiho Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.